HR Execs on the Move

Georgia Medical Care Foundation

www.gmcf.org

 
Since 1972, GMCF has been providing medical peer review and consultative services, utilization and quality management review services for Medicaid Programs.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.gmcf.org
  • 57 Executive Park South NE
    Atlanta, GA USA 30329-2288
  • Phone: 404.327.5920

Executives

Name Title Contact Details

Similar Companies

California Association Of Hospital and Health

California Association Of Hospital & Health is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sacramento, CA. To find more information about California Association Of Hospital & Health, please visit www.calhealth.org

BioInformatics

BioInformatics is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Washington Health System

Washington Health System provides an integrated healthcare system centered around patients and families. They have been dedicated to providing the highest quality care since 1897. With locations throughout Washington and Greene counties in Pennsylvania...

Oxford PharmaGenesis

Oxford PharmaGenesis is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.